These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19426995)

  • 1. Glatiramer acetate treatment in PPMS: why males appear to respond favorably.
    Wolinsky JS; Shochat T; Weiss S; Ladkani D;
    J Neurol Sci; 2009 Nov; 286(1-2):92-8. PubMed ID: 19426995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
    Wolinsky JS; Narayana PA; O'Connor P; Coyle PK; Ford C; Johnson K; Miller A; Pardo L; Kadosh S; Ladkani D;
    Ann Neurol; 2007 Jan; 61(1):14-24. PubMed ID: 17262850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis.
    Laule C; Vavasour IM; Zhao Y; Traboulsee AL; Oger J; Vavasour JD; Mackay AL; Li DK
    Mult Scler; 2010 Jun; 16(6):670-7. PubMed ID: 20558500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study.
    Sajja BR; Narayana PA; Wolinsky JS; Ahn CW;
    Mult Scler; 2008 Jan; 14(1):73-80. PubMed ID: 17881390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate.
    Comi G; Moiola L
    Neurologia; 2002 May; 17(5):244-58. PubMed ID: 12031214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
    Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
    J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
    Basile E; Gibbs E; Aziz T; Oger J
    J Neuroimmunol; 2006 Aug; 177(1-2):161-6. PubMed ID: 16765453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
    Filippi M; Wolinsky JS; Comi G;
    Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
    Meininger V; Drory VE; Leigh PN; Ludolph A; Robberecht W; Silani V
    Amyotroph Lateral Scler; 2009; 10(5-6):378-83. PubMed ID: 19922128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
    Rovaris M; Comi G; Rocca MA; Valsasina P; Ladkani D; Pieri E; Weiss S; Shifroni G; Wolinsky JS; Filippi M;
    Mult Scler; 2007 May; 13(4):502-8. PubMed ID: 17483532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological studies of mitoxantrone in primary progressive MS.
    Pelfrey CM; Cotleur AC; Zamor N; Lee JC; Fox RJ
    J Neuroimmunol; 2006 Jun; 175(1-2):192-9. PubMed ID: 16644023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Bernardi V; Favaretto A; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P; Filippi M
    Neurology; 2009 Apr; 72(15):1330-6. PubMed ID: 19365054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?
    Rovaris M; Comi G; Filippi M
    J Neurol Sci; 2005 Jun; 233(1-2):139-43. PubMed ID: 15949501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response.
    Kovalchin J; Krieger J; Genova M; Collins K; Augustyniak M; Masci A; Hittinger T; Kuca B; Edan G; Braudeau C; Rimbert M; Patel U; Mascioli E; Zanelli E
    J Neuroimmunol; 2010 Aug; 225(1-2):153-63. PubMed ID: 20466440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.